Alpha Paradigm Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

Alpha Paradigm Partners’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$395K	Buy	20,165 +10,761	+114%	+$198K	0.16%	202
2022 Q3	$150K	Sell	9,404 -100,741	-91%	-$1.57M	0.07%	332
2022 Q2	$1.52M	Buy	110,145 +76,009	+223%	+$906K	0.63%	25
2022 Q1	$541K	Sell	34,136 -1,166	-3%	-$20.1K	0.21%	161
2021 Q4	$771K	Buy	+35,302	New	+$963K	0.31%	94

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Alpha Paradigm Partners's RCKT Position: Q4 2022 in Review

Alpha Paradigm Partners increased its Rocket Pharmaceuticals (RCKT) stake by 114% in Q4 2022, buying an estimated $198K and bringing the position to 20,165 shares worth $395K. The position accounts for 0.16% of the portfolio, ranked #202.

Alpha Paradigm Partners first reported a position in RCKT in Q4 2021 and has held it in 5 quarters since. The position peaked at $1.52M in Q2 2022. 167 funds tracked by Wall St. Rank hold RCKT as of Q4 2022.

Alpha Paradigm Partners held 20,165 shares of Rocket Pharmaceuticals worth $395K as of Q4 2022.
Alpha Paradigm Partners bought 10,761 Rocket Pharmaceuticals shares in Q4 2022, an estimated $198K.
Rocket Pharmaceuticals made up 0.16% of Alpha Paradigm Partners's portfolio in Q4 2022, its #202 holding.
Alpha Paradigm Partners first reported a position in Rocket Pharmaceuticals in Q4 2021 and has held it in 5 quarters since.
Alpha Paradigm Partners's Rocket Pharmaceuticals position peaked at $1.52M in Q2 2022.
167 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2022.

Based on Alpha Paradigm Partners's 13F filing for Q4 2022, filed 13 Feb 2023.